Which has stronger valuation and earnings, NRSN or BOLD?

Boundless Bio is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Boundless Bio N/A N/A -$58.20M -$2.86 N/A

Is NRSN or BOLD more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Boundless Bio N/A -70.89% -47.37%

Does the media prefer NRSN or BOLD?

In the previous week, NeuroSense Therapeutics had 9 more articles in the media than Boundless Bio. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 2 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 0.94 beat NeuroSense Therapeutics' score of 0.76 indicating that Boundless Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Boundless Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NRSN or KVAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is NRSN or KVAC more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Keen Vision Acquisition N/A N/A N/A

Do analysts rate NRSN or ALPS?

NeuroSense Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 2,460.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than ALPS Group Inc Ordinary Share. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NRSN or ALPS more profitable?

Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A ALPS Group Inc Ordinary Share N/A N/A N/A

Which has better valuation & earnings, ELTX or NRSN?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is ELTX or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% NeuroSense Therapeutics N/A N/A N/A

Does the media favor ELTX or NRSN?

In the previous week, NeuroSense Therapeutics had 9 more articles in the media than Elicio Therapeutics. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 2 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.80 beat NeuroSense Therapeutics' score of 0.76 indicating that Elicio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRSN or EXOZ more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A eXoZymes N/A -292.15% -158.66%

NeuroSense Therapeutics (NRSN) Competitors

$0.33 -0.07 (-17.21%)

Closing price 04:00 PM Eastern

Extended Trading

$0.34 +0.01 (+3.92%)

As of 07:59 PM Eastern

Compare

NRSN vs. BOLD, KVAC, ALPS, ELTX, and EXOZ

Should you buy NeuroSense Therapeutics stock or one of its competitors? NeuroSense Therapeutics's main competitors and comparable companies include Boundless Bio (BOLD), Keen Vision Acquisition (KVAC), ALPS Group Inc Ordinary Share (ALPS), Elicio Therapeutics (ELTX), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NeuroSense Therapeutics compare to Boundless Bio?

NeuroSense Therapeutics (NASDAQ:NRSN) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NeuroSense Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 2,460.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe NeuroSense Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Boundless Bio is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

NeuroSense Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Boundless Bio has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market.

NeuroSense Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Boundless Bio	N/A	-70.89%	-47.37%

In the previous week, NeuroSense Therapeutics had 9 more articles in the media than Boundless Bio. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 2 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 0.94 beat NeuroSense Therapeutics' score of 0.76 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Boundless Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NeuroSense Therapeutics beats Boundless Bio on 12 of the 13 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Keen Vision Acquisition?

NeuroSense Therapeutics (NASDAQ:NRSN) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, NeuroSense Therapeutics had 11 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 0 mentions for Keen Vision Acquisition. NeuroSense Therapeutics' average media sentiment score of 0.76 beat Keen Vision Acquisition's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Positive
Keen Vision Acquisition	Neutral

NeuroSense Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NeuroSense Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 2,460.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe NeuroSense Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Keen Vision Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

NeuroSense Therapeutics beats Keen Vision Acquisition on 7 of the 9 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to ALPS Group Inc Ordinary Share?

NeuroSense Therapeutics (NASDAQ:NRSN) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

ALPS Group Inc Ordinary Share has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.18	-$2.01M	$0.33	1.17

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NeuroSense Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 2,460.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, NeuroSense Therapeutics had 10 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 1 mentions for ALPS Group Inc Ordinary Share. NeuroSense Therapeutics' average media sentiment score of 0.76 beat ALPS Group Inc Ordinary Share's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Positive
ALPS Group Inc Ordinary Share	Neutral

NeuroSense Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Summary

NeuroSense Therapeutics beats ALPS Group Inc Ordinary Share on 8 of the 12 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Elicio Therapeutics currently has a consensus price target of $19.75, indicating a potential upside of 836.02%. NeuroSense Therapeutics has a consensus price target of $8.50, indicating a potential upside of 2,460.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Elicio Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Elicio Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

NeuroSense Therapeutics' return on equity of 0.00% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
NeuroSense Therapeutics	N/A	N/A	N/A

In the previous week, NeuroSense Therapeutics had 9 more articles in the media than Elicio Therapeutics. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 2 mentions for Elicio Therapeutics. Elicio Therapeutics' average media sentiment score of 1.80 beat NeuroSense Therapeutics' score of 0.76 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NeuroSense Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

NeuroSense Therapeutics beats Elicio Therapeutics on 9 of the 13 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to eXoZymes?

NeuroSense Therapeutics (NASDAQ:NRSN) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

NeuroSense Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 2,460.24%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe NeuroSense Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeuroSense Therapeutics' return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
eXoZymes	N/A	-292.15%	-158.66%

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

eXoZymes has higher revenue and earnings than NeuroSense Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
eXoZymes	$70K	823.93	-$9.16M	-$1.19	N/A

In the previous week, NeuroSense Therapeutics had 10 more articles in the media than eXoZymes. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 1 mentions for eXoZymes. NeuroSense Therapeutics' average media sentiment score of 0.76 beat eXoZymes' score of 0.67 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
NeuroSense Therapeutics	Positive
eXoZymes	Positive

NeuroSense Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, suggesting that its share price is 214% more volatile than the broader market.

Summary

NeuroSense Therapeutics beats eXoZymes on 10 of the 14 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRSN vs. The Competition

Export

Metric	NeuroSense Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.14M	$3.84B	$7.12B	$12.70B
Dividend Yield	N/A	3.61%	2.55%	9.16%
P/E Ratio	N/A	13.66	273.41	25.12
Price / Sales	N/A	1,321.98	670.91	117.13
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	-6.64	15.42	10.43	6.18
Net Income	-$11.12M	-$22.82M	$3.49B	$358.18M
7 Day Performance	-17.33%	-3.59%	-2.99%	-2.34%
1 Month Performance	-31.43%	0.88%	0.02%	-2.50%
1 Year Performance	-75.59%	43.89%	20.19%	9.87%

NeuroSense Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRSN NeuroSense Therapeutics	3.9082 of 5 stars	$0.33 -17.2%	$8.50 +2,460.2%	-65.8%	$15.14M	N/A	N/A	10	Analyst Revision Gap Down
BOLD Boundless Bio	1.1038 of 5 stars	$2.85 -0.7%	N/A	+147.8%	$64.84M	N/A	N/A	64	News Coverage
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
ALPS ALPS Group Inc Ordinary Share	0.6047 of 5 stars	$0.38 -0.5%	N/A	N/A	$62.90M	$4.86M	1.15	N/A
ELTX Elicio Therapeutics	2.9912 of 5 stars	$2.38 -1.1%	$19.75 +728.4%	-81.4%	$62.55M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRSN) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. BOLD, KVAC, ALPS, ELTX, and EXOZ

How does NeuroSense Therapeutics compare to Boundless Bio?

Summary

How does NeuroSense Therapeutics compare to Keen Vision Acquisition?

Summary

How does NeuroSense Therapeutics compare to ALPS Group Inc Ordinary Share?

Summary

How does NeuroSense Therapeutics compare to Elicio Therapeutics?

Summary

How does NeuroSense Therapeutics compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroSense Therapeutics (NRSN) Competitors

NRSN vs. BOLD, KVAC, ALPS, ELTX, and EXOZ

How does NeuroSense Therapeutics compare to Boundless Bio?

Do institutionals & insiders believe in NRSN or BOLD?

Do analysts rate NRSN or BOLD?

Which has stronger valuation and earnings, NRSN or BOLD?

Which has more risk & volatility, NRSN or BOLD?

Is NRSN or BOLD more profitable?

Does the media prefer NRSN or BOLD?

Summary

How does NeuroSense Therapeutics compare to Keen Vision Acquisition?

Does the media prefer NRSN or KVAC?

Which has more risk & volatility, NRSN or KVAC?

Do institutionals and insiders hold more shares of NRSN or KVAC?

Do analysts prefer NRSN or KVAC?

Is NRSN or KVAC more profitable?

Which has better valuation & earnings, NRSN or KVAC?

Summary

How does NeuroSense Therapeutics compare to ALPS Group Inc Ordinary Share?

Which has better earnings & valuation, NRSN or ALPS?

Is NRSN or ALPS more profitable?

Do institutionals and insiders believe in NRSN or ALPS?

Do analysts rate NRSN or ALPS?

Does the media favor NRSN or ALPS?

Which has more risk & volatility, NRSN or ALPS?

Summary

How does NeuroSense Therapeutics compare to Elicio Therapeutics?

Do analysts prefer ELTX or NRSN?

Which has more risk & volatility, ELTX or NRSN?

Which has better valuation & earnings, ELTX or NRSN?

Is ELTX or NRSN more profitable?

Does the media favor ELTX or NRSN?

Do institutionals and insiders have more ownership in ELTX or NRSN?

Summary

How does NeuroSense Therapeutics compare to eXoZymes?

Do analysts recommend NRSN or EXOZ?

Is NRSN or EXOZ more profitable?

Do institutionals & insiders have more ownership in NRSN or EXOZ?

Which has stronger earnings and valuation, NRSN or EXOZ?

Does the media refer more to NRSN or EXOZ?

Which has more risk & volatility, NRSN or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRSN vs. The Competition

NeuroSense Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools